Nautilus Biotechnology, Inc. - Common Stock (NAUT)
2.4100
+0.00 (0.00%)
NASDAQ · Last Trade: Mar 4th, 9:31 AM EST
Detailed Quote
Previous Close
2.410
Open
-
Bid
2.390
Ask
2.520
Day's Range
N/A - N/A
52 Week Range
0.6200 - 3.080
Volume
42
Market Cap
299.07M
PE Ratio (TTM)
-5.128
EPS (TTM)
-0.5
Dividend & Yield
N/A (N/A)
1 Month Average Volume
225,475
Chart
About Nautilus Biotechnology, Inc. - Common Stock (NAUT)
Nautilus Biotechnology Inc is a pioneering company focused on advancing the field of proteomics, which involves the large-scale study of proteins and their functions within biological systems. By leveraging cutting-edge technologies, Nautilus aims to provide researchers and healthcare professionals with innovative tools and solutions to gain deeper insights into protein behavior, interactions, and modifications. Their mission is to facilitate discoveries in various areas, including drug development, disease research, and personalized medicine, ultimately contributing to improved health outcomes and scientific knowledge. Read More
Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform
SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025.
• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early Access Program to use Iterative Mapping, Nautilus’ technology designed to measure billions of intact protein molecules, ahead of broader commercial availability
SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference.
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026.
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein standards and affinity reagents position the organizations to probe disease-associated proteoforms at unprecedented resolution
Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and neurodegenerative disease research
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
• Buck Institute’s deployment of Nautilus’ instrument generates tau proteoform data, providing external validation of the company’s next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can advance human health and longevity • Data presentation at the 2025 HUPO World Congress seminar “Redefining Proteomics with Single-Molecule Iterative Mapping” on November 10
SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025.
SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2025 before market open on Tuesday, October 28, 2025.
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent strategic developments. This significant uptick reflects investor confidence in the life sciences giant's aggressive expansion into high-growth sectors,
NEW YORK, NY / ACCESS Newswire / September 16, 2025 / Investor Summit Group, the premier destination for virtual microcap conferences, is proud to announce the schedule for its upcoming Q3 Investor Summit Virtual on Sept 16, 2025.
SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences.
SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025.
• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease
